Solid Biosciences Financials
SLDB Stock | USD 5.86 0.45 8.32% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.22 | 0.2077 |
|
| |||||
Current Ratio | 6.18 | 8.9367 |
|
|
The essential information of the day-to-day investment outlook for Solid Biosciences includes many different criteria found on its balance sheet. An individual investor should monitor Solid Biosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Solid Biosciences.
Net Income |
|
Solid | Select Account or Indicator |
Understanding current and past Solid Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Solid Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Solid Biosciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Solid Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Solid Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Solid Biosciences' management manipulating its earnings.
Solid Biosciences Stock Summary
Solid Biosciences competes with Century Therapeutics, Edgewise Therapeutics, C4 Therapeutics, Mineralys Therapeutics,, and Cullinan Oncology. Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Solid Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US83422E1055 |
CUSIP | 83422E105 83422E204 |
Location | Massachusetts; U.S.A |
Business Address | 500 Rutherford Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.solidbio.com |
Phone | 617 337 4680 |
Currency | USD - US Dollar |
Solid Biosciences Key Financial Ratios
Return On Equity | -0.66 | ||||
Price To Sales | 3.65 X | ||||
Gross Profit | 13.62 M | ||||
EBITDA | (93.43 M) | ||||
Net Income | (96.02 M) |
Solid Biosciences Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 103.5M | 171.2M | 232.4M | 260.3M | 164.9M | 152.1M | |
Other Current Liab | 52K | 6.4M | 8.1M | 14.1M | 7.8M | 7.4M | |
Net Tangible Assets | 80.0M | 132.1M | 208.2M | 211.7M | 243.4M | 255.6M | |
Net Debt | (69.0M) | (149.6M) | (117.1M) | (126.8M) | (47.8M) | (50.1M) | |
Retained Earnings | (316.3M) | (404.6M) | (476.8M) | (562.7M) | (658.8M) | (625.8M) | |
Accounts Payable | 7.1M | 3.3M | 4.5M | 3.2M | 2.0M | 4.0M | |
Cash | 76.0M | 154.7M | 119.1M | 155.4M | 74.0M | 92.2M | |
Other Current Assets | 1.5M | 4.2M | 14.7M | 8.8M | 10.1M | 5.1M | |
Total Liab | 23.4M | 39.1M | 24.2M | 48.6M | 38.5M | 42.5M | |
Total Current Assets | 86.3M | 158.9M | 222.6M | 219.6M | 129.7M | 135.9M | |
Common Stock | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Net Invested Capital | 80.0M | 132.1M | 208.2M | 211.7M | 126.5M | 129.6M | |
Net Working Capital | 68.0M | 134.4M | 199.0M | 197.1M | 115.2M | 139.8M | |
Capital Surpluse | 396.3M | 536.6M | 684.9M | 774.5M | 890.6M | 597.6M | |
Capital Stock | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Short Term Debt | 1.9M | 4.4M | 3.0M | 5.1M | 4.6M | 3.5M |
Solid Biosciences Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Income | 1.6M | 115K | 64K | 2.6M | 7.0M | 7.4M | |
Gross Profit | (2.8M) | (3.9M) | (45.1M) | 5.7M | (76.6M) | (72.7M) | |
Operating Income | (119.3M) | (88.4M) | (72.3M) | (106.5M) | (104.3M) | (109.5M) | |
Ebit | (119.3M) | (88.3M) | (72.3M) | (99.3M) | (96.0M) | (100.8M) | |
Research Development | 94.7M | 64.9M | 58.7M | 78.4M | 76.6M | 60.6M | |
Ebitda | (116.5M) | (84.4M) | (69.3M) | (96.9M) | (93.4M) | (98.1M) | |
Cost Of Revenue | 2.8M | 3.9M | 58.7M | 2.4M | 76.6M | 80.4M | |
Income Before Tax | (117.2M) | (88.3M) | (72.2M) | (86.0M) | (96.0M) | (100.8M) | |
Net Income | (115.6M) | (90.1M) | (72.1M) | (65.5M) | (96.0M) | (100.8M) | |
Income Tax Expense | (1.6M) | 1.8M | (64K) | (20.5M) | (18.4M) | (17.5M) | |
Net Interest Income | 1.6M | 115K | 64K | 2.6M | 7.0M | 7.4M |
Solid Biosciences Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Investments | (31.5M) | 7.5M | (141.2M) | (182.8M) | 30.5M | 32.0M | |
Change In Cash | (10.3M) | 78.7M | (33.9M) | 36.0M | (81.4M) | (77.3M) | |
Free Cash Flow | (97.1M) | (57.5M) | (79.0M) | (101.0M) | (95.7M) | (100.5M) | |
Depreciation | 2.8M | 3.9M | 3.0M | 2.4M | 2.6M | 2.1M | |
Other Non Cash Items | (277K) | (20K) | (81K) | (18.3M) | (2.0M) | (2.1M) | |
Capital Expenditures | 4.4M | 899K | 1.3M | 3.0M | 1.5M | 2.7M | |
Net Income | (117.2M) | (88.3M) | (72.2M) | (86.0M) | (96.0M) | (100.8M) | |
End Period Cash Flow | 76.4M | 155.1M | 121.2M | 157.2M | 74.0M | 92.8M | |
Change To Netincome | 14.2M | 11.6M | 13.5M | 7.5M | 8.7M | 7.7M |
Solid Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Solid Biosciences's current stock value. Our valuation model uses many indicators to compare Solid Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Solid Biosciences competition to find correlations between indicators driving Solid Biosciences's intrinsic value. More Info.Solid Biosciences LLC is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Solid Biosciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Solid Biosciences' earnings, one of the primary drivers of an investment's value.Solid Biosciences LLC Systematic Risk
Solid Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Solid Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Solid Biosciences LLC correlated with the market. If Beta is less than 0 Solid Biosciences generally moves in the opposite direction as compared to the market. If Solid Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Solid Biosciences LLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Solid Biosciences is generally in the same direction as the market. If Beta > 1 Solid Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Solid Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Solid Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Solid Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Solid Biosciences November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Solid Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Solid Biosciences LLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Solid Biosciences LLC based on widely used predictive technical indicators. In general, we focus on analyzing Solid Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Solid Biosciences's daily price indicators and compare them against related drivers.
Information Ratio | (0.17) | |||
Maximum Drawdown | 24.49 | |||
Value At Risk | (8.66) | |||
Potential Upside | 7.44 |
Complementary Tools for Solid Stock analysis
When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |